A61K 9 - Medicinal preparations characterised by special physical form

Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
11/2004
11/24/2004	CN1176658C Aseptic freeze-dried prostaglandin injection and its preparing method and use
11/24/2004	CN1176656C Freeze-drying composition for injection
11/24/2004	CN1176655C Refapentine or rifampin liposome perfusate, injection and preparation process thereof
11/24/2004	CN1176653C Slow-releasing Anixidan capsule
11/24/2004	CN1176649C Inhalant of Shumaputan dry-powder and its preparation method
11/24/2004	CN1176648C Hawthorn leaves total flavone soft capsule and its preparing method
11/23/2004	WO2004103378A1 Immediate-release pharmaceutical dosage form comprising polymorphous tibolone
11/23/2004	US6822002 Use of L-carnitine and its alkanoyl derivatives as osmotic agents in solutions for medical use
11/23/2004	US6822000 Orthopedic implants or vehicles for the sustained delivery of pharmaceutical, cosmetic and agricultural agents contain hydrogen bonding groups and alpha-hydroxy acid-containing groups
11/23/2004	US6821975 Beta-carboline drug products
11/23/2004	US6821974 Vasodilation; hypotensive agents; cardiovascular disorders
11/23/2004	US6821968 Stable taurolidine electrolyte solutions
11/23/2004	US6821959 Characterized by weak bonds such as the hydrogen bond compared to the same free antibiotic, have equal or higher microbiological activity or therapeutic effectiveness, with reduced molar doses of antibiotic and are less toxic
11/23/2004	US6821951 An echinocandin/carbohydrate complex in an oral formulation to enhance heat resistance/shelf life; desolventizing a solution of an echinocandin or echinocandin/carbohydrate complex and a carbohydrate sprayed on a carrier; fungicides
11/23/2004	US6821934 Flowable preparations of the water-in-oil emulsion type having an increased water content
11/23/2004	US6821780 Complete nutrient medium for use as a cosmetic and cosmetic use thereof
11/23/2004	US6821532 Methods and compositions for the treatment of benign prostatic hypertrophy
11/23/2004	US6821531 Fibrous cellulose excipient comprising cellulose ii lattice with bulk density of 0.2-0.5 g/cm3 and tap density of 0.4-0.7 g/cm3; for use as binder, filler, disintegrant in solid dosage forms
11/23/2004	US6821530 Providing a mixture comprising the polymeric material and a monomer comprising a first catechol group and reactive group; oxidizing mixture; polymerizing monomer via the first catechol group and reactive group to form polymer
11/23/2004	US6821523 Topical administration of pharmacologically active bases in the treatment of warts
11/23/2004	US6821508 Composition and method for topical nail treatment
11/23/2004	US6821479 Preservation of biological materials using fiber-forming techniques
11/23/2004	CA2317106C Method and composition of an oral preparation of itraconazole
11/23/2004	CA2295061C Storage-stable ophthalmic compositions comprising diclofenac and ofloxacin
11/23/2004	CA2260835C Method of improving the growth or the efficiency of feed conversion of an animal and compositions for use therein
11/23/2004	CA2245766C Compositions useful in the phototherapeutic treatment of proliferative skin disorders
11/23/2004	CA2242035C Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
11/23/2004	CA2185242C Sustained release tablet containing diclofenac-na
11/23/2004	CA2171963C Dextran esters, the preparation thereof and the use thereof for coating or embedding drugs
11/23/2004	CA2075077C Stevia extract-containing liquid internal medicine and method of preparing the same
11/18/2004	WO2004099393A1 Method for storing tumor cells
11/18/2004	WO2004099377A2 An autologous upregulation mechanism allowing optimized cell type-specific and regulated gene expression cells
11/18/2004	WO2004099332A2 Wood adhesives containing solid residues of biomass fermentations
11/18/2004	WO2004099287A1 Polyethylene glycol/polycation block copolymer
11/18/2004	WO2004098642A1 Migraine relief composition and methods of using and forming same
11/18/2004	WO2004098620A1 Activated carbon infusion solution, preparation method therefor and use thereof for the manufacture of drug for treating cancer
11/18/2004	WO2004098614A1 Freeze-dried preparation containing methylcobalamin and process for producing the same
11/18/2004	WO2004098594A2 Dosage form containing pantoprazole as active ingredient
11/18/2004	WO2004098593A1 Amorphous clopidogrel hydrogen sulfate composition
11/18/2004	WO2004098592A1 Composition containing oxazolidinone derivative
11/18/2004	WO2004098581A2 Oral spray to reduce cold symptoms and duration of same
11/18/2004	WO2004098577A2 Dosage form containing (s)-pantoprazole as active ingredient
11/18/2004	WO2004098576A1 Abuse-resistant transdermal dosage form
11/18/2004	WO2004098575A1 Ultraviolet-shielding type patch
11/18/2004	WO2004098574A1 Nanocomposite drug delivery composition
11/18/2004	WO2004098573A1 An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation
11/18/2004	WO2004098572A1 Biphasic release of glipizide from monocompartment osmotic dosage form
11/18/2004	WO2004098571A1 Cold remedy composition comprising zinc salts
11/18/2004	WO2004098570A1 Nanoparticulate bioactive agents
11/18/2004	WO2004098569A1 Micelle delivery system loaded with a pharmaceutical agent
11/18/2004	WO2004098568A2 Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
11/18/2004	WO2004098567A2 Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
11/18/2004	WO2004098566A2 Chewable lozenge cold remedy composition and method for making same
11/18/2004	WO2004098565A2 Implantable controlled release bioactive agent delivery device
11/18/2004	WO2004098564A2 Biodegradable nanoparticles comprising an aminoglycoside and a polymer like a polysaccharide
11/18/2004	WO2004098562A2 Controlled release solid dosage nifedipine formulations
11/18/2004	WO2004098561A2 Particulate materials
11/18/2004	WO2004098560A1 Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
11/18/2004	WO2004098537A2 Activation agents on the surface of encapsulation vesicles
11/18/2004	WO2004098524A2 Lipid platinum complexes and methods of use thereof
11/18/2004	WO2004098513A2 Nasal administration of the lh-rh analog leuprolide
11/18/2004	WO2004098503A2 Drug releasing biodegradable fiber for delivery of therapeutics
11/18/2004	WO2004098493A2 Binder composition and method for processing poorly compressible drugs into tablets of predetermined hardness and friability
11/18/2004	WO2004098491A2 METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES
11/18/2004	WO2004098472A1 Transdermal delivery systems and methods
11/18/2004	WO2004098454A2 Low profile components for patient infusion device
11/18/2004	WO2004098390A2 Rf medical device
11/18/2004	WO2004092231A3 Macromolecules auto-assembled and photopolymerised around carbon nanotubes a method for production and application thereof
11/18/2004	WO2004087052A3 Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
11/18/2004	WO2004082749A3 Medical devices with enhanced ultrasonic visibility
11/18/2004	WO2004082625A3 Self-emulsifying compositions, methods of use and preparation
11/18/2004	WO2004078102A3 Sterilization of beclomethasone drug particles for pulmonary delivery
11/18/2004	WO2004073632A3 Rapid absorption selective 5-ht agonist formulations
11/18/2004	WO2004071486B1 Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
11/18/2004	WO2004071421A3 Sustained release formulation of n-(2-propylpentanoyl) glycinamide and related compounds
11/18/2004	WO2004066983A3 Controlled release of highly soluble agents
11/18/2004	WO2004022126A3 Method of treating a systemic disease
11/18/2004	WO2003087021A8 Nanoparticle delivery systems and methods of use thereof
11/18/2004	WO2003075829A3 Tasteless directly compressible fast-dissolving complexes and pharmaceutical formulations thereof
11/18/2004	US20040230183 Drug delivery device and syringe for filling the same
11/18/2004	US20040230182 Drug delivery through encapsulation
11/18/2004	US20040229930 treatment of protein kinase related disorders.
11/18/2004	US20040229919 As diuretic agent, as an agent for preventing heart or heart tissue damages caused by metabolic or ionic abnormalities associated with ischemia, in the treatment of thrombosis, angina pectoris, asthma, hypertension, nephroedema, pulmonary edema, primary and secondary aldosteronism, Bartter's syndrome
11/18/2004	US20040229912 Polymeric delivery formulations of leuprolide with improved efficacy
11/18/2004	US20040229854 Administering to a patient in need thereof an effective amount of a pharmaceutical formulation in the form of an immediate-release peroral dosage unit, comprising tibolone, wherein the pharmaceutical formulation has a bioavailability, in vivo, of 3 alpha -OH tibolone
11/18/2004	US20040229849 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
11/18/2004	US20040229842 Use of lipid conjugates in the treatment of diseases
11/18/2004	US20040229835 Immunostimulatory nucleic acid molecules
11/18/2004	US20040229834 PREFERENTIAL CLASSIFICATON BETWEEN CANCER CELLS; OBTAIN SAMPLE, MONITOR SAMPLE FOR PREFERENTIAL ENZYMATIC ACTIVITY, EVALUATE DIFFERENTIATED CELLS; for of detecting presence or absence or level of a polynucleotide sequence encoding heparanase in a biological sample
11/18/2004	US20040229831 Compositions and methods for non-parenteral delivery of oligonucleotides
11/18/2004	US20040229828 Administering a therapeutically effective amount of at least one pharmacologically acceptable oligonucleotide at least 10 nucleotides in length
11/18/2004	US20040229821 Orally administrable pharmaceutical compositions and methods for preventing food-drug interaction
11/18/2004	US20040229794 Lipophilic drug delivery vehicle and methods of use thereof
11/18/2004	US20040229793 Compositions and methods for less immunogenic protein formulations
11/18/2004	US20040229776 Pharmaceutical compositions for hepatitis C viral protease inhibitors
11/18/2004	US20040229775 Bactericide drug
11/18/2004	US20040229358 Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
11/18/2004	US20040229266 RNA interference mediating small RNA molecules
11/18/2004	US20040229212 Recombinant human mannan-binding lectin
11/18/2004	US20040229038 Nanoparticulate meloxicam formulations

1 ... 1908 1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 1923 1924 1925 1926 1927 1928 ... 2991